Curaleaf Deal Brings Portuguese Cannabis Brand Back to UK Market

Curaleaf Laboratories will manufacture and distribute medical cannabis grown by Herdade das Barrocas, a Portuguese cultivator whose products dropped out of British dispensaries last year, under a supply partnership the two companies announced on June 22, 2026. The arrangement routes Barrocas flower through Curaleaf’s UK facility for packaging and distribution to prescribers, with the first products due to reach patients from June 2026.

Neither company disclosed financial terms, supply volumes, or whether the deal is exclusive. What is confirmed is the structure: Herdade das Barrocas cultivates the flower in Portugal, and Curaleaf Laboratories handles the regulated manufacturing, quality assurance and distribution inside the UK.

A return, not a debut

Both sides described the agreement as a “reintroduction,” and the wording carries weight. Barrocas-branded flower had been available to UK patients before it disappeared from the market — an absence the announcement does not explain.

The reason sits in Portugal. The grower, formally Sociedade Agrícola Monte das Barrocas and based in the Évora district, was caught up in a Portuguese criminal investigation known as Operation Erva Daninha, and its cannabis operations were forcibly suspended between July and November 2025, according to Portuguese cannabis-sector reporting. Portugal’s medicines regulator, Infarmed, restored the company to its published list of authorized operators in November 2025, with clearances spanning cultivation, manufacturing, import and export. Portuguese reporting indicates prosecutors then closed the case against the company and its chief executive, Jorge Godinho, in May 2026, leaving the two no longer defendants.

That sequence is the real backdrop to the word “reintroduce.” For Curaleaf, partnering now means picking up a grower that has just cleared the legal and licensing cloud that pushed its products off UK shelves in the first place.

Why Curaleaf is the gateway

For Curaleaf Laboratories, the Barrocas deal is the latest in a run of supply arrangements that position the company less as a single brand and more as the UK’s manufacturing and distribution gateway for overseas growers. The MHRA-approved manufacturer, based in Sunderland and part of Curaleaf International since 2019, signed a supply deal with Australian Natural Therapeutics Group in November 2025 and a partnership with Berlin’s Sanity Group in February 2026, each built on the same template: a foreign cultivator supplies the product, and Curaleaf provides the EU-GMP manufacturing, quality systems and route to UK prescribers.

The facility itself recently became, by its own account, the first in Britain to manufacture medical cannabis suppositories, part of a steady widening of what it can produce domestically. That capability is what makes the gateway model work: international producers reach British patients without building their own UK compliance and distribution operation, which is the expensive, slow part of entering a regulated medicines market.

Curaleaf already runs its own Portuguese cultivation and Spanish extraction inside a vertically integrated European chain, and its US-listed parent has broadened its European footprint through deals such as the full buyout of Germany’s Four 20 Pharma. Layering third-party flower from an independent grower on top of that vertical supply is the notable part of the Barrocas agreement — and it concentrates more product through one processor, a trade-off that swaps resilience for the producer against dependence on a single partner.

What the deal does and doesn’t settle

The UK is the obvious prize. Britain’s medical cannabis market has expanded quickly, with imports roughly doubling over the past year as overseas producers chase a growing private-prescription base — one that remains concentrated among a small number of prescribing doctors. More cultivators competing for that demand generally means more choice for clinicians and, potentially, pressure on price. Portuguese and Spanish growers have increasingly cultivated for export to Europe’s larger medical markets, and the UK is among the most important destinations.

But the announcement leaves the operational questions open. The companies have not said how much flower will move, on what timeline beyond an initial launch, or at what price. The Portuguese supply end is not fully settled either: Barrocas’s operating license lapsed on June 1, 2026, and Godinho has attributed the gap to an administrative renewal delay at Infarmed rather than any operational fault, according to Portuguese coverage. Until that renewal is confirmed and product actually ships, the partnership is an announced plan rather than an executed one.

For UK prescribers and patients, the practical test is straightforward: whether Barrocas strains reappear on dispensary menus in the coming months, and whether Curaleaf can keep them in stock.